Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Economic Analysis of Alliance A041202 CLL Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Observational Study in CLL Patients Receiving BR
- Status
- COMPLETED
- Phase
- N/A
Lenalidomide and Obinutuzumab for Previously Untreated CLL
- Status
- WITHDRAWN
- Phase
- PHASE2
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE3
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
- Status
- COMPLETED
- Phase
- PHASE1
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
- Status
- COMPLETED
- Phase
- PHASE2
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Status
- COMPLETED
- Phase
- PHASE3
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1